10.7.2017 13:32 | Business Wire
Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs
Biogen (NASDAQ: BIIB) announced today the appointment of Amy Chevalier Efantis as Vice President of Government Affairs, effective July 17.
Ms. Efantis brings to Biogen more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company’s federal and state government affairs activities from Biogen’s Washington, D.C., office.
She joins Biogen from Boehringer Ingelheim Pharmaceuticals, where she led the company’s Washington-based Government Affairs and Public Policy team as Executive Director and Head of Office. Ms. Efantis was also a Senior Director for the Pharmaceutical Research and Manufacturers of America (PhRMA), working with member companies on strategies related to legislation impacting the industry. Prior to her move to biopharma, she served as Legislative Director to former Alabama Congressman Artur Davis and as Senior Legislative Assistant to former Wisconsin Congressman Tom Barrett.
“We are pleased to welcome Amy to Biogen and our mission to innovate medicine in neuroscience,” said Susan Alexander, Executive Vice President, Corporate Services. “Her experience will be invaluable in our ongoing efforts to promote access to life-changing therapies in multiple sclerosis, to implement newborn screening for spinal muscular atrophy (SMA) and to raise awareness of the importance of early detection of Alzheimer's disease.”
Ms. Efantis holds an undergraduate degree in history and political science and a professional certification in secondary education from the University of Wisconsin.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com . Follow us on social media – Twitter , LinkedIn , Facebook , YouTube .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
KSA-MOCI21.7.2017 20:35 | pressemeddelelse
Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces
JANSSEN21.7.2017 14:11 | pressemeddelelse
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
IPSEN21.7.2017 13:29 | pressemeddelelse
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
SCHLUMBERGER21.7.2017 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2017 Results
NRI-SECURETECHNOLOGIES21.7.2017 09:02 | pressemeddelelse
NRI Secure Launches Japan's First "Blockchain Assessment" Service
SARTORIUS21.7.2017 07:02 | pressemeddelelse
Business Figures for the First Half of 2017: Sartorius Continues to Grow
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum